Selank Vial Has No Vacuum? What That Does—and Does Not—Prove

Typical receiving scenario—not a customer claim:

A buyer opens a new Selank kit and notices that one vial does not behave like the last shipment. There is no obvious sense of negative pressure. The flip-off cap looks normal, the stopper is still seated, and the lyophilised material looks unchanged. The immediate question is understandable: does “no vacuum” mean the vial leaked?

The short answer is not by itself. A buyer’s impression of vacuum is not a validated container-closure integrity test. Headspace pressure depends on how the vial was stoppered, what gas was used, the vial and stopper system, elapsed storage time and temperature. A real loss of integrity can change headspace pressure or gas composition, but the reverse conclusion does not follow: an unfamiliar pressure sensation alone cannot establish a leak, sterility, identity, purity or Selank content.[1–5]

That distinction matters because “vacuum,” “seal” and “sterile” are often treated as if they were the same claim. They are not.

First separate the three questions

When a Selank vial is described as having “no vacuum,” three different questions have usually been compressed into one.

1. What was the intended headspace condition at stoppering? A lyophilised vial may be closed under reduced pressure, at a chosen partial pressure, or with a selected gas in the headspace. Without the supplier’s process specification, the buyer does not know the target against which the vial is being judged.
2. Has the container-closure system maintained its barrier? Container-closure integrity, usually shortened to CCI, concerns the whole package: glass vial, elastomeric stopper and crimped overseal acting together. It is not the same as merely seeing an intact cap.[1,2]
3. What does this say about the material inside? Even a properly sealed vial still requires separate evidence for identity, purity and quantitative content. Conversely, a chromatographic purity figure does not prove package integrity.

This is why a useful supplier inquiry begins with a precise observation rather than a conclusion. “The vial has no vacuum” is less informative than: the stopper appears seated, the crimp is intact, there is no visible crack, the cake looks unchanged, and the buyer observed a different pressure response compared with other vials from the same shipment. Those details do not diagnose the cause, but they give the supplier something concrete to investigate.

Reduced headspace pressure is a process choice, not a universal visual standard

During lyophilisation, vials are commonly stoppered inside the freeze-dryer. The chamber pressure, any gas backfill and the chosen stoppering conditions influence the pressure and gas composition left above the dried product. The resulting headspace is therefore part of a defined manufacturing process, not a universal feature that every lyophilised vial must present in exactly the same way.

An older pressure study illustrates another complication. Vials sealed at very low chamber pressure did not preserve one perfectly fixed pressure forever. Their internal pressure rose after sealing, initially more quickly and then more slowly, with stopper moisture desorption and gas permeation among the factors discussed by the author.[3] The study does not supply a pass/fail rule for a modern Selank vial. It does show why a buyer cannot infer the original stoppering condition from a casual observation months later.

Vial volume, stopper material, formulation, storage time and temperature can all matter. Even barometric pressure at the place of inspection affects the pressure difference across the closure. A buyer comparing two shipments without the process records may therefore be comparing different package configurations, different stoppering targets or different storage histories—not necessarily one sealed vial and one failed vial.

What container-closure integrity actually asks

CCI asks whether the package continues to provide the barrier required for the product over its lifecycle. FDA guidance describes the container-closure system as the complete set of packaging components that contain and protect the product. For products represented as sterile, the agency expects package integrity to prevent penetration by microbial contaminants and other external hazards.[1,2]

Manufacturers do not establish that with a fingertip impression or by looking at the flip-off button. Published CCI methods use controlled, qualified measurements. Examples include vacuum-decay testing, helium leak testing, tracer-gas methods and laser-based headspace analysis of pressure or gas composition. Which method is suitable depends on the specific vial, stopper, headspace, product and defect model.[1,4–6]

In one validated vacuum-decay study for a lyophilised vial system, the method detected laser-drilled defects of at least 5 μm under the study conditions.[4] In another study, laser-based headspace oxygen analysis was developed for freeze-dried vials and modelled gas ingress through defined defects; the authors stressed that detection time depends on package volume, defect size and storage conditions.[5] These are demonstrations of method capability for particular systems. They are not a DIY threshold, and they do not prove that a different Selank vial has or has not leaked.

The practical lesson is simple: a controlled measurement needs a known target, positive controls, method sensitivity and acceptance criteria. “It did not feel like the last vial” has none of those elements.

Why an intact cap is reassuring—but incomplete evidence

The aluminium overseal keeps the stopper in compression against the vial finish. Capping studies show that residual seal force is influenced by the vial, stopper, crimp and capping process. A controlled target range can support a tight closure, while a visibly or mechanically loose component may justify investigation.[6]

Still, the outside appearance cannot reveal every possible defect. A cap can look ordinary while the stopper-to-glass interface, glass body or process history requires closer evaluation. The reverse is also true: cosmetic variation does not automatically establish a functional leak.

Useful receiving observations include:

• cracked or chipped glass;
• a stopper that is visibly displaced rather than evenly seated;
• a loose, distorted or incomplete crimp;
• staining or dried material in the neck or closure region;
• unexplained differences concentrated in one vial or repeated across a kit;
• packaging damage or a documented transport event.

These observations are triage information. They do not turn the buyer into a CCI laboratory.

What not to use as a home-made seal test

An improvised test can create the very defect it is supposed to detect. Puncturing a stopper, prying at the crimp, immersing the vial, applying pressure, transferring the material or repeatedly manipulating the closure changes the package and destroys the value of the original observation. It can also make a later supplier investigation much harder.

The same caution applies to sound, bubbles or the movement of a liquid added by the buyer. Those observations depend on the action taken and are not equivalent to a validated, non-destructive CCI method. This article therefore does not provide a puncture, pressure, immersion or reconstitution procedure.

If a vial differs from the agreed specification, isolate the unit in its received condition, retain the outer packaging and record what was observed before changing anything. For a business buyer, traceability is more useful than an improvised demonstration.

A better evidence request for a Selank supplier

A supplier should not be expected to disclose every proprietary process parameter in a first message. But a serious B2B inquiry can ask for enough information to distinguish a documented package system from a vague assurance.

1. Define the exact item and lot

Record the product name, per-vial specification, kit quantity, lot or batch identifier, order date and which vial numbers showed the difference. MY PEPTIDE’s standard wholesale format is one kit of ten vials of the same product; different products may be combined as complete kits, not as five-plus-five mixed vials within one kit. The current commercial rule is set out in the MY PEPTIDE Wholesale Terms.

2. Ask whether reduced pressure is an actual specification

Do not assume it. Ask whether this vial configuration is intended to be stoppered under reduced pressure, under an inert-gas backfill, or near atmospheric pressure—and whether the supplier has a defined acceptance criterion. A verbal statement that “all peptide vials have vacuum” is too broad to evaluate.

3. Ask how closure integrity is controlled

Useful answers identify the vial/stopper/crimp configuration, the capping control used and the type of CCI or package-integrity verification applied during qualification, validation, stability work or routine monitoring. The answer should connect the method to the actual package system rather than naming a laboratory technique in the abstract.

4. Separate package evidence from material evidence

A peptide COA may contain identity, chromatographic purity, water or other results, depending on what was actually tested. It does not automatically report headspace pressure or container-closure integrity. Ask which batch the document covers and which question each test answers.

5. Look for a pattern, not a dramatic one-vial conclusion

One unusual vial can trigger an investigation. Several similarly affected units can change its scope. Record how many vials were inspected, how many differed and whether the difference appeared in one kit, one shipping carton or multiple lots. The batch-consistency guide explains why repeated observations should be linked to batch records rather than generalized to a supplier’s entire catalogue.

6. Agree on the investigation and disposition

The supplier’s response should state what evidence it needs, who will review the unit, whether a retained sample or same-lot unit will be examined, and how the business decision will be documented. “Looks fine” and “probably lost vacuum” are both incomplete without the package target and the investigation basis.

A compact receiving record

For a Selank kit, a buyer can preserve the useful facts in a short record:

The record avoids claims it cannot support. It does not say “sterile,” “contaminated,” “full potency” or “fake” based on package appearance. It preserves the chain of facts needed for a real investigation.

The decision rule for a wholesale buyer

Treat a different pressure response as a question to investigate, not as a pass/fail instrument.

• If the supplier never defined a headspace-pressure target, the buyer cannot grade the vial against an assumed vacuum standard.
• If there is visible package damage, a displaced stopper, an incomplete crimp or another concrete defect, document and escalate it without manipulating the vial.
• If reduced pressure is a claimed specification, ask how that claim is measured, at what point in the product lifecycle, and against which acceptance criteria.
• Keep CCI evidence separate from identity, purity and quantitative content evidence.

For a Selank product inquiry, send the product name, per-vial specification, number of complete kits, lot information when applicable and the unedited receiving observations. That gives the supplier a question it can answer with records instead of guesswork.

Editorial method and limits

MY PEPTIDE’s editorial team prepared this guide for B2B procurement review using FDA container-closure guidance and published pharmaceutical packaging studies. AI assisted with research organization, bilingual drafting and image creation; the cited claims were checked against the linked source records. The cover is a conceptual illustration, not batch evidence. No independent packaging laboratory or clinical professional has reviewed this draft. The article does not establish the condition of a specific vial and does not provide a sterility, quality or suitability decision.

References

1. U.S. Food and Drug Administration. Container and Closure System Integrity Testing in Lieu of Sterility Testing as a Component of the Stability Protocol for Sterile Products. Guidance for Industry. 2008. FDA guidance.
2. U.S. Food and Drug Administration. Sterile Drug Products Produced by Aseptic Processing—Current Good Manufacturing Practice. Guidance for Industry. 2004. FDA guidance.
3. Crist B. Time-dependence of pressure in lyophilization vials. PDA Journal of Pharmaceutical Science and Technology. 1994;48(4):189–196. PMID: 7804818. PubMed.
4. Patel J, Mulhall B, Wolf H, Klohr S, Guazzo DM. Vacuum decay container closure integrity leak test method development and validation for a lyophilized product-package system. PDA Journal of Pharmaceutical Science and Technology. 2011;65(5):486–505. DOI: 10.5731/pdajpst.2011.00780. PubMed.
5. Hede JO, Fosbøl PL, Berg SW, Dahl S. Container Closure Integrity Testing—Method Development for Freeze-Dried Products Using Laser-Based Headspace Oxygen Analysis. PDA Journal of Pharmaceutical Science and Technology. 2019;73(2):170–180. DOI: 10.5731/pdajpst.2018.008680. PubMed.
6. Mathaes R, Mahler HC, Vorgrimler L, et al. The Pharmaceutical Capping Process—Correlation between Residual Seal Force, Torque Moment, and Flip-off Removal Force. PDA Journal of Pharmaceutical Science and Technology. 2016;70(3):218–229. DOI: 10.5731/pdajpst.2015.006106. PMID: 26797973. PubMed.